Search Results
Jul 27, 2026, 06:45 ET PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead the Procept Class Action Lawsuit
artificially and unsustainably inflated Procept's reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept's undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class
More news about: Robbins Geller Rudman & Dowd LLP
Jul 27, 2026, 06:10 ET Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
2026. Biologics license applications (BLAs) for both ASC37 once-monthly SQ formulation and oral formulation will be submitted to the FDA after Phase III completion. ASC35, a next-generation GLP-1R/GIPR dual peptide agonist, also has 41 alpha amino acids and will be submitted as a BLA as well.Compared
More news about: Ascletis Pharma Inc.
Jul 26, 2026, 16:30 ET CCOI INVESTOR ALERT: RGRD Law Files Class Action Lawsuit Against Cogent Communications Holdings, Inc. and Announces that Investors with Substantial Losses Have Opportunity to Lead the Cogent Class Action Lawsuit
wavelength in a timely manner; (iii) that, as a result of (i)-(ii) above, defendants had materially misrepresented customer demand for Cogent's optical wavelength services and the nature of Cogent's purported "backlog" of wavelength orders; (iv) that, as a result of (i)-(iii) above, Cogent was not on track
More news about: Robbins Geller Rudman & Dowd LLP
Jul 25, 2026, 13:39 ET NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)
données issues du programme complet de développement clinique de NewAmsterdam évaluant l'obicetrapib, notamment les essais de phase III BROADWAY, BROOKLYN et TANDEM de phase III, qui ont démontré des réductions statistiquement significatives du LDL-C pouvant atteindre 40 % avec l'obicetrapib en monothérapie
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 25, 2026, 12:00 ET Okuma America Corporation expondrá en el IMTS 2026 con una amplia gama de productos
automatización asociadoLB2000 EX III MYW Cargador robótico Okuma Plus con palé (ORL+)
More news about: Okuma America Corporation
Jul 24, 2026, 22:00 ET ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
that: (i) the Company engaged in an undisclosed related party transaction; (ii) the Company used channel stuffing to create an appearance of revenue; (iii) the Company lacked adequate internal controls; and (iv) as a result, Defendants' statements about the Company's business, operations, and prospects
More news about: ClaimsFiler
Jul 24, 2026, 22:00 ET Futu Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Futu - FUTU
(ii) as a result, the Company was reasonably likely to face regulatory penalties, including the disgorgement of ill-gotten gains and other penalties; (iii) as a result of the foregoing, the Company's financial results were overstated; and (iv) as a result of the foregoing, defendants' positive statements
More news about: ClaimsFiler
Jul 24, 2026, 22:00 ET Zillow Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Zillow Group, Inc. - ZG, Z
(ii) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (iii) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (iv) as a result, Defendants' statements about Zillow's
More news about: ClaimsFiler
Jul 24, 2026, 22:00 ET PicS Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PicS N.V. - PICS
R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends
More news about: ClaimsFiler
Jul 24, 2026, 17:45 ET Xryma Plc : mécanisme de liquidité avant la cotation et processus de formation du cours
de l'article 49, paragraphe 2, points a) à d) (sociétés à patrimoine important, associations constituées en personne morale, etc.) de l'Arrêté, ou (iii) à qui elle peut être légalement communiquée d'une autre manière ; toute autre personne au Royaume-Uni ne doit pas prendre de décision sur la base de
More news about: Xryma Plc
Jul 24, 2026, 16:45 ET INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Grail Class Action Lawsuit
reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence management
More news about: Robbins Geller Rudman & Dowd LLP
Jul 24, 2026, 16:15 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are in clinical or preclinical development and the risk of failure is high and can unexpectedly
More news about: Nektar Therapeutics
Jul 24, 2026, 14:50 ET PRIM INVESTOR ALERT: Primoris Services Corporation Investors with Substantial Losses Have Opportunity to Lead the Primoris Class Action Lawsuit
risks of significant fixed-price renewable energy projects that were experiencing material cost overruns, execution problems, and schedule delays; and (iii) accordingly, defendants' statements regarding Primoris' estimating processes, project execution, ability to manage project risk, financial performance,
More news about: Robbins Geller Rudman & Dowd LLP
Jul 24, 2026, 14:34 ET Okuma America Corporation to Exhibit at IMTS 2026 with Comprehensive Lineup
Paired Automation SystemLB2000 EX III MYW Okuma Robot Loader Plus with pallet (ORL+)
More news about: Okuma America Corporation
Jul 24, 2026, 13:18 ET EQPT Investors Have Opportunity to Lead EquipmentShare.com Inc Securities Lawsuit
(ii) EquipmentShare had not terminated or substantially reduced a number of the transactions with entities owned or controlled by the co-founders; (iii) as a result, EquipmentShare's financial statements were materially misleading; and (iv) as a result of the foregoing, defendants' positive statements
More news about: THE ROSEN LAW FIRM, P. A.
Jul 24, 2026, 12:52 ET ActivatedYou by Maggie Q Launches Vital Strength, ActivatedYou's First Muscle-Supporting, Creatine Supplement: A Performance Formula for Lean Muscle, Recovery, and Total-Body Resilience
apparel brand Qeep Up, ActivatedYou founder, and actor—best known for her roles in Nikita, Designated Survivor, and Mission: Impossible III — Maggie Q uses her name to advocate for those in need. Maggie's personal health struggles led her to conduct extensive research in nutrition and inspired
More news about: ActivatedYou
Jul 24, 2026, 10:45 ET INVESTOR DEADLINE: Intuit Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - INTU
tax-related business, particularly in its Turbo Tax business, as a result of, among other things, increasing competitive and pricing pressures; and (iii) accordingly, Intuit's previously issued 2026 TurboTax revenue growth guidance was unreliable and/or unrealistic.On May 20, 2026, during pre-market
More news about: Robbins Geller Rudman & Dowd LLP
Jul 24, 2026, 08:33 ET Brave Healer Productions Releases Vol. 3 of The Caregiver's Advocate: A Complete Guide to Support and Resources
Kathleen Plummer Gordon, Meira Gross, Dr. Makeba Morgan Hill, Theodore Ihenetu, Kaley Johnson, Esther C. Kane, Denyse LeFever, Beth Meek, Carlos Olivas III, Kelly Ott, Barbara French Ritchey, Susan J. Ryan, Kerry Ann Sandsmark, Veronica Scheers, Leslie Sedille, and Nancy Y. Treaster.Among the topics
More news about: Brave Healer Productions
Jul 24, 2026, 08:31 ET Xryma Plc: Liquiditätsfazilität vor der Börsennotierung und Preisfindungsverfahren
„Verordnung") fallen, (ii) die unter Artikel 49(2)(a) bis (d) (vermögende Unternehmen, eingetragene Vereinigungen usw.) der Verordnung fallen, oder (iii) an die sie anderweitig rechtmäßig übermittelt werden darf; alle anderen Personen im Vereinigten Königreich sollten keine Maßnahmen auf der Grundlage
More news about: Xryma Plc
Jul 24, 2026, 08:00 ET HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
that the study was optimally structured with a three-year follow-up period to demonstrate a statistically significant reduction in late-stage (Stage III and IV) cancer diagnoses.Concealment of Limitations: The action centers on whether GRAIL selectively promoted favorable top-line results
More news about: Hagens Berman Sobol Shapiro LLP
Jul 24, 2026, 07:00 ET INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Roblox Corporation (RBLX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
while continuing to be "enormously bullish" on their tech rollouts as well as claiming to be able to "rely on [their] tremendous organic growth"; and (iii) Roblox relied far too heavily on viral events to drive growth and failed to communicate to investors the potential knock-on impacts of the age verification
More news about: Robbins Geller Rudman & Dowd LLP
Jul 24, 2026, 07:00 ET Charter Announces Second Quarter 2026 Results
to or when they become due and to fund our operations and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets;our ability to comply with all covenants in our indentures and credit facilities, any violation of
More news about: Charter Communications, Inc.
Jul 24, 2026, 05:25 ET Xryma Plc: Mecanismo de liquidez previo a la cotización y proceso de determinación de precios
modificada, la "orden"), (ii) comprendidas en el artículo 49(2)(a) a (d) (empresas de alto patrimonio neto, asociaciones constituidas, etc.) de la orden, o (iii) a quienes se les pueda comunicar legalmente de otro modo; cualquier otra persona en el Reino Unido no debe tomar ninguna medida basándose en esta publicación
More news about: Xryma Plc
Jul 24, 2026, 05:00 ET Turbopower, LLC Awarded Position on U.S. Air Force 10-Year Multiple-Award IDIQ Contract Supporting U.S. and Allied T56 Fleets
a maximum ceiling value of $343.2 million and enables Turbopower to compete for task orders supporting depot-level repair and overhaul of T56 Series III and Series 3.5 engines, modules, and components for the United States Air Force (USAF), United States Navy (USN), and Foreign Military Sales (FMS) customers.
More news about: Turbopower LLC
Jul 24, 2026, 01:00 ET Xryma Plc : Pre-Listing Liquidity Facility and Price Discovery Process
(as amended, the "Order"), (ii) falling within article 49(2)(a) to (d) (high net worth companies, incorporated associations, etc.) of the Order, or (iii) to whom it may otherwise be lawfully communicated; any other persons in the United Kingdom should not take any action on the basis of this publication
More news about: Xryma Plc